GlassScriptPhysician profile
Barry E Troyan
NPI 1295733483
$14,051.78
in general payments reported to CMS, 2019-2025
55 companies · $1,786 in 2025
The $1,786 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,985 · 2020: $1,175 · 2021: $3,862 · 2022: $1,895 · 2023: $1,699 · 2024: $1,649 · 2025: $1,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,134.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,492.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,529.38 | 2020-2021 | |
| Lilly USA, LLC | $1,029.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $931.50 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Abbvie INC. | $864.82 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $838.15 | 2021-2025 | |
| Glaxosmithkline, LLC. | $709.96 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $586.84 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Amarin Pharma, INC. | $432.32 | 2019-2022 | |
| Esperion Therapeutics, INC. | $362.99 | 2020-2023 | Nexletol |
| Corium, LLC | $333.68 | 2023-2025 | Azstarys, Azstarys |
| Corcept Therapeutics | $332.43 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.93 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $287.53 | 2019-2025 | Repatha, Otezla |
| Astellas Pharma US INC | $257.97 | 2019-2024 | Veozah |
Show all 54 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Troyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.